NYSE: ABBV
AbbVie Inc Stock

ABBV Price
$82.89
Fair Value Price
N/A
Market Cap
$122.41B
52 Week Low
$64.50
52 Week High
$100.83
P/E
17.56x
P/B
8.32x
P/S
4.46x
PEG
0.41x
Dividend Yield
5.43%
Revenue
$36.23B
Earnings
$6.96B
Gross Profit Margin
73.60%
Operating Margin
25.94%
Net Profit Margin
19.20%
Debt to Equity
9.17
Operating Cash Flow
$15B
Beta
0.83
Next Earnings
Oct 30, 2020
Ex-Dividend
Oct 14, 2020
Next Dividend
Nov 16, 2020

Zen Score

High
Medium
Low
47
Industry average

Reasons for this score

ABBV ($82.89) is trading below its intrinsic value of $692.69, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
ABBV is good value based on its earnings relative to its share price (17.56x), compared to the US market average 38.92x)
Valuation
ABBV is good value based on its earnings relative to its share price (17.56x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

1 of 12

ABBV News

Valuation

ABBV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
17.56x
Industry
-11.07x
Market
38.92x
ABBV is good value based on its earnings relative to its share price (17.56x), compared to the US market average 38.92x)
Valuation
ABBV is good value based on its earnings relative to its share price (17.56x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

ABBV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.32x
Industry
7.85x
Market
65.04x
ABBV is good value based on its book value relative to its share price (8.32x), compared to the US market average (65.04x)
Valuation
ABBV is poor value based on its book value relative to its share price (8.32x), compared to the US Drug Manufacturers - General industry average (7.85x)
Valuation

ABBV price to earnings growth (PEG)

For valuing profitable companies with growth potential
ABBV is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.41x)
Valuation

ABBV's financial health

Profit margin

Revenue
$8.6B
Net Income
$3.0B
Profit Margin
34.90%
ABBV's Earnings (EBIT) of $9.40B are insufficient to safely cover interest payments on company debt ($87.43B)
Financials
ABBV's profit margin has increased (+6.60%) in the last year from (12.60%) to (19.20%)
Financials

Assets to liabilities

Assets
$91.2B
Liabilities
$98.6B
Debt to equity
-9.04
ABBV's short-term liabilities ($24.65B) exceed its short-term assets ($21.26B)
Financials
ABBV's long-term liabilities ($110.15B) exceed its short-term assets ($21.26B)
Financials
ABBV's debt has increased relative to shareholder equity (9.17), over the past 5 years ago (8.79)
Financials
ABBV's debt to equity ratio (9.17) is considered high
Financials

Cash flow

Operating
$3.8B
Investing
-$129.0M
Financing
-$2.4B
ABBV's operating cash flow ($14.73B) may not be sufficient to safely service the company's debt ($87.43B)
Financials

AbbVie Stock FAQ

(NYSE: ABBV) AbbVie trades on the NYSE under the ticker symbol ABBV. AbbVie stock quotes can also be displayed as NYSE: ABBV.
(NYSE: ABBV) AbbVie stock price per share is $82.89 today (as of Oct 21, 2020).
(NYSE: ABBV) AbbVie's 52-week high was $100.83, and its 52-week low was $64.50. It is currently -17.79% from its 52-week high and 28.51% from its 52-week low.
(NYSE: ABBV) AbbVie's market cap is $122.41B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

AbbVie's market cap is calculated by multiplying ABBV's current stock price of $82.89 by ABBV's total outstanding shares of 1,476,742,215.
(NYSE: ABBV) AbbVie currently has 1,476,742,215 outstanding shares. With AbbVie stock trading at $82.89 per share, the total value of AbbVie stock (market capitalization) is $122.41B.

AbbVie stock was originally listed at a price of $35.12 in Jan 2, 2013. If you had invested in AbbVie stock at $35.12, your return over the last 7 years would have been 136.02%, for an annualized return of 13.05%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics